Andrew K. Balo — Executive Vice President of Clinical, Regulatory and Global Access at DexCom

Mr. Andrew K. Balo, also known as Andy, has been an Executive Vice President of Clinical, Regulatory and Global Access at Dexcom, Inc. since March 3, 2017. Mr. Balo serves as Vice President of Regulatory and Clinical Affairs at Post-Hypothermia Corporation. Mr. Balo served as an Executive Vice President of Clinical, Regulatory, Quality and Global Access at Dexcom, Inc. since January 2015 until March 3, 2017. Mr. Balo served as Senior Vice President of Clinical & Regulatory Affairs at Dexcom, Inc. since March 2008 until January 2015. He oversees all of Dexcom's clinical trials, statistical analyses and regulatory submissions. He is an industry expert in regulatory strategies and sits on several FDA panels including cardiovascular, neurological and gastrointestinal as the industry representative. He is instrumental in bringing several key medical devices to the market including a neurological cooling device, mechanical and tissue-based heart valves, pacemakers, pacing leads, aortic grafts and electrophysiology mapping devices and has gained approval for over thirty PMA and PMA supplements. He served as Vice President of regulatory and clinical affairs of Dexcom, Inc. from February 2002 to March 2008. He held positions as Vice President, Regulatory and Clinical Affairs for Post-Hypothermia Corporation and Endocardial Solutions, Inc. During the 1990s, he held several positions at St. Jude Medical including Vice President, Regulatory, Clinical and Technical Services and Corporate Vice President, Quality, Regulatory and Clinical Affairs. He held senior management positions at Pacesetter and Baxter. Mr. Balo received a BS in Microbiology and Chemistry from the University of Maryland and has studied at UCLA and Stanford.